Table 2.
Outcome analysis: survival and recurrence.
| Overall survival | Cause specific survival | Freedom From Recurrence | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 5 year | 10 year | p | 5 year | 10 year | p | 5 year | 10 year | p | |
| Postoperative predictors | |||||||||
| Histology | |||||||||
| Thymoma | 93.6 | 86.3 | 0.001 | 98.6 | 97.1 | 0.018 | 91.7 | 89.3 | 0.001 |
| TC | 73.3 | 66.7 | 77.8 | 75.6 | 65.9 | 61.4 | |||
| Residual tumor classification | |||||||||
| R0 | 91.0 | 83.5 | 0.007 | 94.4 | 93.3 | 0.017 | 87.8 | 85.2 | 0.001 |
| R1 + 2 | 78.9 | 65.0 | 84.2 | 80.0 | 62.5 | 56.3 | |||
| Tumor Stage* | |||||||||
| I-II | 93.3 | 86.1 | 0.032 | 96.7 | 96.7 | 0.001 | 93.0 | 92.1 | 0.001 |
| III-IV | 80.4 | 72.6 | 85.7 | 82.3 | 69.6 | 62.5 | |||
| Preoperative predictors | |||||||||
| ASA | |||||||||
| 1 | 100 | 100 | 0.348 | 100 | 100 | 0.240 | 88.9 | 88.9 | 0.849 |
| 2 | 85.9 | 81.3 | 93.8 | 90.6 | 88.5 | 85.2 | |||
| 3 | 89.4 | 80.3 | 93.9 | 93.9 | 88.5 | 86.9 | |||
| 4 | 71.4 | 57.1 | 71.4 | 71.4 | 71.4 | 71.4 | |||
| ALI | |||||||||
| high | 87.4 | 80.5 | 0.229 | 94.3 | 94.3 | 0.036 | 90.0 | 89.9 | 0.030 |
| low | 81.5 | 70.4 | 85.2 | 81.5 | 76.9 | 73.1 | |||
| CFS | |||||||||
| low | 91.5 | 83.1 | 0.074 | 96.6 | 95.8 | 0.001 | 92.0 | 90.2 | 0.001 |
| high | 71.9 | 71.9 | 78.1 | 78.1 | 58.6 | 58.6 | |||
| GPS | |||||||||
| 0 | 88.7 | 88.9 | 0.776 | 93.9 | 93.0 | 0.074 | 88.9 | 88.0 | 0.009 |
| 1 | 84.6 | 80.9 | 92.3 | 92.3 | 84.0 | 80.0 | |||
| 2 | 66.7 | 66.7 | 66.7 | 66.7 | 50.0 | 40.0 | |||
| HS-mGPS | |||||||||
| 0 | 90.8 | 88.2 | 0.172 | 97.4 | 97.4 | 0.013 | 93.1 | 93.1 | 0.002 |
| 1 | 84.8 | 72.7 | 89.4 | 87.9 | 80.6 | 77.4 | |||
| 2 | 66.7 | 66.7 | 66.7 | 66.7 | 50.0 | 40.0 | |||
| TET-aGPS | |||||||||
| 0 | 91.6 | 86.3 | 0.034 | 96.8 | 96.8 | 0.006 | 91.1 | 91.1 | 0.006 |
| 1 | 79.6 | 70.4 | 85.2 | 83.3 | 76.5 | 72.0 | |||
| SII | |||||||||
| low | 88.9 | 79.4 | 0.690 | 96.8 | 96.8 | 0.045 | 91.2 | 91.2 | 0.056 |
| high | 85.2 | 78.7 | 88.5 | 86.9 | 81.4 | 79.3 | |||
Three different parameters were tested in the Kaplan Meier survival analysis: overall survival, cause specific survival and freedom from recurrence. Accepted clinical predictors such as histology, tumor stage and residual tumor classification were tested along with ASA and composite clinical scores. Cut-offs: The Youden Index was employed to define the optimal ALI cutoff of 26.1 and 655 for the SII; the median pretreatment CRP value of 3 mg/L was used to dichotomize patients into high and low CRP groups for the CFS score.
ASA American Society of Anesthesiology classification of Physical Health, ALI advanced lung cancer inflammation index, CFS CRP/Fibrinogen Prognostic score, GPS Glasgow Prognostic Score, HS-mGPS the high-sensitivity modified Glasgow Prognostic Score, TET-aGPS thymic epithelial tumor adapted Glasgow Prognostic Score, SII systemic immune-inflammation index, *Masaokoa- Koga tumor stage.